Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.
Actively Recruiting
Researchers are conducting a prospective, multicenter, observational national study to better understand lung cancer among Tunisian patients. This study includes patients with any stage of lung cancer who have a confirmed diagnosis. It aims to collect clinical, treatment, and disease progression information to improve knowledge about lung cancer in this population. Participants will be observed without receiving experimental treatments, as this is not an interventional trial. The study will follow patients receiving care in pulmonology, oncology, radiation oncology, and thoracic surgery departments. Data collection will include information from diagnosis confirmed by histology or cytology at least three months before joining the study. During the study, researchers will monitor important health outcomes such as diagnostic delay on day one, survival, and relapse at 12 months. They will also assess how well treatment recommendations are followed. Participants will be followed for at least a year to gather this data, with no additional treatments administered as part of the study.